Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

37.59
+0.14000.37%
Post-market: 37.590.00000.00%19:30 EDT
Volume:429.25K
Turnover:16.16M
Market Cap:3.62B
PE:-19.22
High:38.27
Open:37.74
Low:37.24
Close:37.45
52wk High:42.68
52wk Low:24.24
Shares:96.27M
Float Shares:94.37M
Volume Ratio:0.75
T/O Rate:0.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9561
EPS(LYR):-1.2849
ROE:-16.22%
ROA:-11.54%
PB:3.02
PE(LYR):-29.25

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman

Reuters
·
Apr 10

Ideaya Biosciences Inc - Enters Clinical Collaboration Agreement With Astrazeneca On April 8, 2026 - SEC Filing

Reuters
·
Apr 09

IDEAYA, AstraZeneca partner to test IDE849 with Imfinzi in small cell lung cancer

Reuters
·
Apr 09

IDEAYA Biosciences Inc - Co to Sponsor Study; AstraZeneca to Supply Imfinzi - SEC Filing

THOMSON REUTERS
·
Apr 09

IDEAYA Biosciences Inc - Agreement to Evaluate Ide849 With Imfinzi in Extensive-Stage Small Cell Lung Cancer - SEC Filing

THOMSON REUTERS
·
Apr 09

IDEAYA Biosciences Inc - Advancing Global Phase 1 Trial for Ide849 in Dll3 Upregulated Solid Tumors - SEC Filing

THOMSON REUTERS
·
Apr 09

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Norfolk Southern, Denali

Reuters
·
Apr 07

BUZZ-U.S. STOCKS ON THE MOVE-Tyson Foods, Atmus Filtration, Avis Budget

Reuters
·
Apr 06

BUZZ-U.S. STOCKS ON THE MOVE-Legence, Valero Energy, Stereotaxis

Reuters
·
Apr 06

BUZZ-U.S. STOCKS ON THE MOVE-Soleno Therapeutics, Ideaya Biosciences, Profusa

Reuters
·
Apr 06

Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (PTHS), IDEAYA Biosciences (IDYA) and Viridian Therapeutics (VRDN)

TIPRANKS
·
Apr 06

BUZZ-IDEAYA Biosciences rises as early-stage cancer trial starts

Reuters
·
Apr 06

IDEAYA enrolls first patient in Phase 1 trial of KAT6/7 inhibitor IDE574

Reuters
·
Apr 06

IDEAYA Biosciences Announces First-Patient-in for Phase 1 Trial of Ide574, a Potential First-in Class Dual Inhibitor of Kat6/7 to Target Multiple Solid Tumor Indications, Including Breast, Prostate, Crc, and Lung Cancer

THOMSON REUTERS
·
Apr 06

Should IDEAYA’s DLL3 Combo Trial and Early IDE849 Signals Prompt a Rethink From IDYA Investors?

Simply Wall St.
·
Apr 04

IDEAYA Biosciences Price Target Maintained With a $52.00/Share by Wedbush

Dow Jones
·
Mar 31

Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and IDEAYA Biosciences (IDYA)

TIPRANKS
·
Mar 31

BUZZ-U.S. STOCKS ON THE MOVE-Agnico Eagle Mines, ProPetro, Kezar

Reuters
·
Mar 30

BUZZ-U.S. STOCKS ON THE MOVE-Insmed, United Therapeutics, CrowdStrike

Reuters
·
Mar 30

BRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Combination Study Of Ide849, Dll3 Top1 Adc, And Ide161, Parg Inhibitor, In Dll3 Upregulated Solid Tumor Indications, Including Sclc, Nets, Necs, And Melanoma

Reuters
·
Mar 30